

# List of Contributors

## Editors

**Univ.-Prof. Dr. med. Richard Greil**  
Universitätsklinik für Innere Medizin III  
Paracelsus Medizinische Privatuniversität  
Salzburg, Austria  
E-mail: r.greil@salk.at

**Dr. med. Dipl. Ing. biomed. inf. Lisa Pleyer**  
Universitätsklinik für Innere Medizin III  
Paracelsus Medizinische Privatuniversität  
Salzburg, Austria  
E-mail: l.pleyer@salk.at

**PD Dr. med. Daniel Neureiter, M.A.**  
Universitätsinstitut für Pathologie  
Paracelsus Medizinische Privatuniversität  
Salzburg, Austria  
E-mail: d.neureiter@salk.at

**Dr. med. Victoria Faber**  
Universitätsklinik für Innere Medizin III  
Paracelsus Medizinische Privatuniversität  
Salzburg, Austria  
E-mail: v.faber@salk.at

## Authors

**Prof. Dr. med. Justus Duyster**  
III. Medizinische Klinik und Poliklinik  
Klinikum rechts der Isar  
Technische Universität München  
E-mail: justus.duyster@lrz.tum.de

**Dr. med. Thomas Melchardt**  
Universitätsklinik für Innere Medizin III  
Paracelsus Medizinische Privatuniversität  
Salzburg, Austria  
E-mail: t.melchardt@salk.at

**Doz. Dr. med. Nikolas von Bubnoff**  
III. Medizinische Klinik und Poliklinik  
Klinikum rechts der Isar  
Technische Universität München  
E-mail: n.bubnoff@lrz.tum.de

**Dr. med. Lukas Weiss**  
Universitätsklinik für Innere Medizin III  
Paracelsus Medizinische Privatuniversität  
Salzburg, Austria  
E-mail: lu.weiss@salk.at

## About the Editors



**Univ. Prof. Dr. Richard Greil** studied medicine at the Medical University of Innsbruck, where he also had his education for Internal Medicine. He became board certified for internal medicine in 1990, had his habilitation in 1992 with the specific topic of oncogenes and their role in normal and

neoplastic B-cell development, board certified for hematology and medical oncology in 1995, was appointed associate professor and deputy chief of the Department of Hematology and Oncology of the Innsbruck Medical University in 1996. He was the founding member and medical director of the Tyrolean Cancer Research Institute in 2001. In 2004 Prof. Greil was appointed full professor and director of the IIIrd Medical Department with Hematology, Medical Oncology, Hemostaseology, Infectious Disease and Rheumatology at the Private Medical University Hospital in Salzburg and founded the Laboratory of Immunological and Molecular Cancer Research (LIMCR) in Salzburg which he is heading. He is the president of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie), vice president of the ABCSG (Austrian Breast and Colorectal Cancer Study Group) and panel member of the German Hodgkin Study Group (GHSg) and many other trial groups. Prof. Greil has a basic research focus on the molecular biology and immunology of leukemias and myelomas, he has authored or co-authored more than 150 publications in peer reviewed journals and many book chapters, and regularly served as reviewer for journals like J Exp Med, Blood, Leukemia, Ann Oncol, J Immunol, Int J Cancer, Oncogene. He serves as reviewer for granting

agencies like the MRC UK, the Italian Ministry of Research, the Mildred Scheel Foundation and the European Commission. Prof. Greil is a member of many international research societies among them the American Society of Hematology (ASH), the American Association of Medical Oncology (ASCO), and the American Association of Cancer Research (AACR) as well as of the European Society of Medical Oncology (ESMO) where he is a regular reviewer and author of minimal recommendation guidelines on growth factors, leukemias and lymphomas. He is the member of the Hematology Malignancies Faculty of ESMO and the ESMO ethics committee.



**Dr. Lisa Pleyer** was born in Zell am See, Austria. She completed her M.D. at the Leopold Franzens University in Innsbruck and her D.I. at the Private University for Medical Informatics in Hall in Tirol. Dr. Pleyer then specialised in Haematology and Oncology under the direction of Professor Richard Greil. She works in the Haematology Outpatients Department at St. John's Hospital, Salzburg, Austria and also provides clinical training and lectures in Haematology at the Paracelsus Medical University, Salzburg. Dr. Pleyer's research interests focus on myeloproliferative diseases, including the underlying cellular and molecular biology, emerging therapies and the impact of concomitant infections. She has recently established a nationwide azacitidine registry with the aim of facilitating further scientific research.



**Dr. Daniel Neureiter** was born in Jülich, Germany and completed his M.D. as well as his consultant of pathology at the University of Erlangen-Nuernberg and Institute of Pathology (Prof. Dr. Th. Kirchner). Here, main research projects dealt with the association of chronic inflammatory diseases and

the extracellular matrix components. After changing to the Institute of Pathology at Salzburg (Prof. Dr. O. Dietze), he was promoted to an assistant professor at the Paracelsus Private Medical University Salzburg and is now chief senior consultant with major responsibility for solid tumours and hematopathology. His main research interest is the morphological and molecular embryonic differentiation patterning (such as  $\beta$ -Catenin or Hedgehog pathway) during human tumorigenesis.



**Dr. Victoria Faber** was born in Waidhofen an der Ybbs, Austria. She completed her MTA diploma in 1972 in Innsbruck and became a specialist for blood and bone marrow cytology. Dr. Faber completed her M.D. at the University of Vienna in 1999. She then specialized in haematology and

oncology under the direction of Professor Richard Greil. In 2002, Dr. Faber completed a diploma in palliative medicine, which is her main focus of interest. She is currently the head of the Routine Hematological Laboratory as well as of the Palliative Medical Unit of the 3rd Medical Department at the St. Johann's Hospital in Salzburg. Dr. Faber also lectures students at the Private Medical Paracelsus University in Salzburg, Austria.